This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. AbbVie has bought a psychedelic compound from a little ...

AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, for up to $1.2bn, including an upfront payment and development milestones.

AbbVie has written the next chapter in its epic quest to treat psychiatric disorders, agreeing to buy a psychedelic drug candidate from Gilgamesh Pharmaceuticals for up to $1.2 billion. Bloomberg ...

AbbVie could be heading for its second acquisition in the space of a month, with reports emerging of late-stage negotiations with Gilgamesh Pharmaceuticals, a central nervous system (CNS) drug ...